Stockscreener 앱 받기
3.80
2.81%
-0.11
시간 외 거래:
3.85
0.05
+1.32%
전일 마감가:
$3.91
열려 있는:
$3.96
하루 거래량:
5.25M
Relative Volume:
0.93
시가총액:
$1.17B
수익:
$360.78M
순이익/손실:
$-23.91M
주가수익비율:
-48.66
EPS:
-0.0781
순현금흐름:
$13.07M
1주 성능:
-3.80%
1개월 성능:
-15.93%
6개월 성능:
-38.81%
1년 성능:
+1.33%
1일 변동 폭
$3.78
$3.96
1주일 범위
$3.78
$4.1414
52주 변동 폭
$2.23
$6.51
맨카인드 Stock (MNKD) Company Profile
명칭
Mannkind Corp
전화
818-661-5000
주소
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
3.80 | 1.22B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
470.72 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
759.24 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
830.79 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
182.45 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
313.77 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
맨카인드 Stock (MNKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-10-10 | 개시 | Leerink Partners | Outperform |
| 2025-07-16 | 재개 | H.C. Wainwright | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-10 | 개시 | Wedbush | Outperform |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-12-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-10-10 | 개시 | Wedbush | Outperform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 개시 | Oppenheimer | Outperform |
| 2019-10-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2018-02-28 | 다운그레이드 | Maxim Group | Hold → Sell |
| 2017-11-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-10 | 개시 | H.C. Wainwright | Buy |
| 2017-10-06 | 재확인 | Maxim Group | Buy |
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-05-10 | 재확인 | Piper Jaffray | Underweight |
| 2016-05-10 | 재확인 | RBC Capital Mkts | Underperform |
| 2016-01-06 | 재확인 | Piper Jaffray | Underweight |
| 2016-01-06 | 재확인 | RBC Capital Mkts | Underperform |
| 2015-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | 다운그레이드 | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-05-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 재확인 | MLV & Co | Hold |
| 2015-04-16 | 재확인 | RBC Capital Mkts | Outperform |
모두보기
맨카인드 주식(MNKD)의 최신 뉴스
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease - Yahoo Finance
MannKind Corp (MNKD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CT drugmaker raises $50M after FDA approval of new treatment - Hartford Business Journal
H.C. Wainwright reiterates MannKind stock rating on FDA approval By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates MannKind stock rating on FDA approval - Investing.com
MannKind Corp (MNKD) Cash Flow - TradingKey
MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MNKD|MannKind Corp|Price:3.952|Chg%:-0.178 - TradingKey
MannKind Corp (MNKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MannKind Corp (MNKD) Institutional Confidence - TradingKey
MannKind Corp (MNKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
MannKind Corp (MNKD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MNKD Stock Rises Premarket As FDA Verdict Nears – Retail Optimism Builds - Stocktwits
TradingKey - TradingKey
MannKind Corp (MNKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MannKind Corp (MNKD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
MNKD|MannKind Corp|Price:4.130|Chg%:+0.240 - TradingKey
MannKind (MNKD) Stock Looks Undervalued On Cash Flow Yet Mixed On Broader Checks - Yahoo Finance
MannKind Corporation (MNKD) Shares Surge on FDA Approval and $50M Placement - GuruFocus
MannKind Corporation Raises $50 Million in Private Placement Following FDA Approval of Furoscix ReadyFlow - Kalkine Media
MannKind closes $50M financing, wins FDA nod for Furoscix auto-injector - MassDevice
MannKind Corporation (MNKD) stock price, news, quote and history - Yahoo Finance Singapore
MannKind Announces FDA Approval of Furoscix ReadyFlow, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease - FinanzNachrichten.de
MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Yahoo Finance
MannKind Stock Jumps After FDA Clears Furoscix Auto-Injector, Firm Secures $50 Million PIPE - finance.biggo.com
MannKind Corporation (MNKD) Stock Price, News, Quote & History - Yahoo! Finance Canada
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE - Yahoo Finance
FDA Approves Furosemide Autoinjector for Treatment of Edema in CKD or Heart Failure - Pharmacy Times
H.C. Wainwright reiterates Buy on MannKind stock ahead of PDUFA - Investing.com
MannKind shares surge after FDA approves Furoscix ReadyFlow and company secures $50 million financing - Yahoo Finance
H.C. Wainwright reiterates Buy on MannKind stock ahead of PDUFA By Investing.com - Investing.com Canada
Why is MannKind stock rallying today? - Investing.com
MannKind raises $50 million in private placement led by Frazier - Investing.com
MannKind stock jumps 6% on FDA approval, $50M financing - Investing.com
MannKind Announces $50 Million Private Placement - Yahoo Finance
At-home autoinjector delivers IV-equivalent therapy in under 10 seconds - Stock Titan
MannKind wins FDA approval for Furoscix ReadyFlow autoinjector to treat edema in adults with heart failure or CKD - Bitget
MannKind (MNKD) Set for Potential Growth Ahead of FDA Decision - GuruFocus
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Form 4 MannKind Corp For: 21 July By Investing.com - Investing.com South Africa
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
MannKind EVP David Thomson sells $97,641 in MNKD shares on July 17 By Investing.com - Investing.com South Africa
MannKind EVP David Thomson sells $97,641 in MNKD shares on July 17 - Investing.com India
Form 4 MannKind Corp For: 21 July - Investing.com India
MNKD Stock Price, Quote & Chart - ChartMill
MannKind Executive Sells 123,000 Shares Amid Performance Concerns - Intellectia AI
맨카인드 (MNKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
맨카인드 주식 (MNKD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Castagna Michael | Chief Executive Officer |
Jul 15 '26 |
Option Exercise |
0.00 |
350,260 |
0 |
2,796,979 |
| Singh Sanjay R | EVP Technical Operations |
Jul 15 '26 |
Option Exercise |
0.00 |
70,550 |
0 |
525,761 |
| Thomson David | EVP Genl Counsel & Secretary |
Jul 15 '26 |
Option Exercise |
0.00 |
93,790 |
0 |
920,089 |
| Thomson David | EVP Genl Counsel & Secretary |
Jul 17 '26 |
Sale |
4.05 |
24,109 |
97,641 |
797,554 |
| Binder Steven B. | Director |
Jul 15 '26 |
Option Exercise |
0.00 |
93,790 |
0 |
901,798 |
| Binder Steven B. | Director |
Jul 17 '26 |
Sale |
4.06 |
52,485 |
213,089 |
824,918 |
1.84%
0.91%
자본화:
|
볼륨(24시간):